|

EB-HC01 dual-target CARNK cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Beijing Biotech1

Indications

  • Cholangiocarcinoma1
  • Biliary Tract Cancer1
  • Gallbladder Carcinoma1
  • Extrahepatic Cholangiocarcinoma1
  • Intrahepatic Cholangiocarcinoma1

Other1 trial

Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.